| Ytd | -2.41% | |
| 1y | -2.08% |
| Open | 5.75 | Prev Close | 5.66 | Low | 5.68 | High | 6.10 | Mkt Cap | 135.47M |
| Vol | 29.38K | Avg Vol | 174.70K | EPS | -1.15 | P/E | N/A | Forward P/E | -4.25 |
| Beta | N/A | Short Ratio | 1.53 | Inst. Own | 19.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 4.72 | 200-d Avg | 5.17 | 1yr Est | 15.50 |
COYA News
Here is how Coya Therapeutics, Inc. (COYA) and Quest Diagnostics (DGX) have performed compared to th
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-st
Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of Coya 302 Targeting Regulatory T
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
[url="]Coya Therapeutics, Inc.[/url] (NASDAQ: COYA) (âCoyaâ or the âCompanyâ), a clinical-st
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage bi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Top Wall Street analysts changed outlook for top names. See all changes on analyst ratings page. ONT
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA)
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
On May 12, 2026, Coya Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.32) per share which beat the analys
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage bi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Shares of Coya Therapeutics, Inc. (NASDAQ: COYA - Get Free Report) have been assigned a consensus ra
The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integr
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) wit
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.34) per share which missed the anal
Coya Therapeutics, Inc.2,522,727 Shares of Common StockThis prospectus relates to the resale of up t
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Coya Therapeutics (NASDAQ: COYA - Get Free Report) is projected to announce its Q4 2025 results befo
Coya Therapeutics, Inc. (COYA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimi
Speakers on a Coya Therapeutics (NASDAQ: COYA) webinar outlined the company's scientific rationale a
D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and m
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Coya Therapeutics (NASDAQ:COYA) wit
Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage b
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinic
D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and m
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage bi
HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinic
Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maint
D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and m
D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and m
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage b
D. Boral Capital analyst Jason Kolbert maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and m
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage b
